Biochemical and biological characterization of tumor-associated mutations of p110alpha

Methods in Enzymology
Adam DenleyPeter K Vogt

Abstract

Signaling by class I phosphatidylinositol 3-kinase (PI3K) controls cell growth, replication, motility, and metabolism. The PI3K pathway commonly shows gain of function in cancer. Two small GTPases, Rheb (Ras homolog enriched in brain) and Ras (rat sarcoma viral oncogene), play important roles in PI3K signaling. Rheb activates the TOR (target of rapamycin) kinase in a GTP-dependent manner; it links TOR to upstream signaling components, including the tuberous sclerosis complex (TSC) and Akt (homolog of the Akt8 murine lymphoma viral oncoprotein). Constitutively active, GTP-bound Rheb is oncogenic in cell culture, and activity that requires farnesylation. Ras activates PI3K by recruitment to the plasma membrane and possibly by inducing a conformational change in the catalytic subunit p110 of PI3K. In return, Ras signaling through the MAP kinase (MAPK) pathway is activated by PIP(3), the product of PI3K. Loss of Ras function can interfere with PI3K signaling. Various lines of evidence suggest complementary roles for PI3K and MAPK signaling in oncogenesis.

References

Nov 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·P J CaseyJ E Buss
Aug 2, 1994·Proceedings of the National Academy of Sciences of the United States of America·K HaraT R Jackson
Feb 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·J E DamenG Krystal
May 1, 1996·Genes & Development·M N LioubinL R Rohrschneider
Apr 18, 1997·The Journal of Biological Chemistry·G J ClarkC J Der
Jul 1, 1997·Trends in Biochemical Sciences·B VanhaesebroeckM D Waterfield
Feb 12, 1998·The Journal of Biological Chemistry·M AndjelkovićB A Hemmings
Dec 2, 1999·Experimental Cell Research·B Vanhaesebroeck, M D Waterfield
Jul 18, 2002·Current Biology : CB·Sabine SuireLen Stephens
Jul 20, 2002·Science·Klaus OkkenhaugBart Vanhaesebroeck
Jan 22, 2003·Biochemical and Biophysical Research Communications·Buckminster Farrow, B Mark Evers
May 27, 2003·Nature Cell Biology·Hugo StockerErnst Hafen
May 27, 2003·Nature Cell Biology·Leslie J SaucedoBruce A Edgar
May 29, 2003·Nature Cell Biology·Yong ZhangDuojia Pan
Jul 19, 2003·Genes & Development·Ken InokiKun-Liang Guan
Mar 16, 2004·Science·Yardena SamuelsVictor E Velculescu
May 15, 2004·Molecular and Cellular Biology·Pablo Rodriguez-VicianaFrank McCormick
Jun 24, 2004·Seminars in Cell & Developmental Biology·Ramon Parsons
Jun 24, 2004·Seminars in Cell & Developmental Biology·Julian Downward
Jul 16, 2004·Cancer Biology & Therapy·Kurtis E BachmanBen Ho Park
Oct 7, 2004·Cell Cycle·Yardena Samuels, Victor E Velculescu
Nov 3, 2004·Trends in Cell Biology·Gretchen A RepaskyChanning J Der
Jan 14, 2005·Proceedings of the National Academy of Sciences of the United States of America·Sohye KangPeter K Vogt
Feb 16, 2005·Human Mutation·Yun WangAnne-Lise Børresen-Dale
Apr 28, 2005·Current Biology : CB·Xiaomeng LongJoseph Avruch
May 7, 2005·Cell Cycle·Sohye KangPeter K Vogt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.